CL2004000412A1 - USE OF AN EP2 RECEIVER SELECTIVE ANTAGONIST COMPOUND TO TREAT PULMONARY HYPERTENSION. - Google Patents

USE OF AN EP2 RECEIVER SELECTIVE ANTAGONIST COMPOUND TO TREAT PULMONARY HYPERTENSION.

Info

Publication number
CL2004000412A1
CL2004000412A1 CL200400412A CL2004000412A CL2004000412A1 CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1 CL 200400412 A CL200400412 A CL 200400412A CL 2004000412 A CL2004000412 A CL 2004000412A CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1
Authority
CL
Chile
Prior art keywords
treat
facilitate
pulmonary hypertension
hypertension
treat pulmonary
Prior art date
Application number
CL200400412A
Other languages
Spanish (es)
Inventor
Angelo Constan David Alexander
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2004000412A1 publication Critical patent/CL2004000412A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

USO DE UN AGONISTA SELECTIVO DEL RECEPTOR EP2 PARA TRATAR LA HIPERTENSION PULMONAR, FACILITAR LA FUSION DE ARTICULACIONES, FACILITAR LA REPARACION DE TENDONES Y LIGAMENTOS, REDUCIR LA APARICION DE FRACTURAS SECUNDARIAS, TRATAR LA NECROSIS VASCULAR, FACILITAR LA REPERACION DEL CARTILAGO, FACILITAR LA CURACION DEL HUESO DESPUES DEL TRANSPLANTE DE UN MIEMBRO, FACILITAR LA REGENERACION HEPATICA, FACILITAR LA CURACION DE HERIDAS, REDUCIR LA APARICION DE ULCERAS GASTRICA, TRTAR LA HIPERTENSION, FACILITAR EL CRECIMIENTO DEL ESMALTE DE LOS DIENTES O LAS UNAS DE LOS DEDOS DE LAS MANOS O DE LOS PIES, TRATAR UN GLAUCOMA, TRTAR LA HIPERTENSION OCULAR Y RECUPERAR LAS LESIONES PRODUCIDAS POR UNA ENFERMEDAD METASTASICA DE HUESO.USE OF AN EP2 RECEPTOR SELECTIVE AGONIST TO TREAT PULMONARY HYPERTENSION, FACILITATE FUSION OF ARTICULATIONS, FACILITATE THE REPAIR OF TENDONS AND LIGAMENTS, REDUCE THE APPEARANCE OF SECONDARY FRACTURES, TREAT THE NECROSIS, FACILATION OF FACILITY, PACILULATION OF FACILATION BONE AFTER THE TRANSPLANT OF A MEMBER, FACILITATE THE HEPATIC REGENERATION, FACILITATE THE HEALING OF WOUNDS, REDUCE THE APPEARANCE OF GASTRIC ULCERAS, TREAT HYPERTENSION, FACILITATE THE GROWTH OF THE ENAMEL OF THE TEETH OR ONE OR THE ONE FEET, TREAT A GLAUCOMA, TREAT THE EYE HYPERTENSION AND RECOVER THE INJURIES CAUSED BY A METASTASIC BONE DISEASE.

CL200400412A 2003-03-04 2004-03-02 USE OF AN EP2 RECEIVER SELECTIVE ANTAGONIST COMPOUND TO TREAT PULMONARY HYPERTENSION. CL2004000412A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
CL2004000412A1 true CL2004000412A1 (en) 2005-02-04

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400412A CL2004000412A1 (en) 2003-03-04 2004-03-02 USE OF AN EP2 RECEIVER SELECTIVE ANTAGONIST COMPOUND TO TREAT PULMONARY HYPERTENSION.

Country Status (14)

Country Link
EP (1) EP1601351A1 (en)
JP (1) JP2006519250A (en)
KR (1) KR20050105511A (en)
CN (1) CN1859903A (en)
AU (1) AU2004216898A1 (en)
BR (1) BRPI0408061A (en)
CA (1) CA2518193A1 (en)
CL (1) CL2004000412A1 (en)
MX (1) MXPA05009398A (en)
NZ (1) NZ541828A (en)
PL (1) PL378748A1 (en)
TW (1) TW200424176A (en)
WO (1) WO2004078169A1 (en)
ZA (1) ZA200506532B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
JP4666257B2 (en) * 2003-07-25 2011-04-06 小野薬品工業株式会社 Cartilage-related disease treatment
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR101238525B1 (en) 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Novel benzylamine derivatives as cetp inhibitors
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
RU2493252C2 (en) 2006-03-24 2013-09-20 Чилдрен'З Медикал Сентер Корпорейшн Method to stimulate expansion of haematopoietic stem cells
KR101088942B1 (en) 2006-07-28 2011-12-01 화이자 프로덕츠 인코포레이티드 Ep2 agonists
JP5426389B2 (en) 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション Methods for enhancing tissue regeneration
US7939671B2 (en) * 2007-08-21 2011-05-10 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
AU2009224329B2 (en) * 2008-03-12 2013-11-07 Ube Corporation Pyridylaminoacetic acid compound
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
CA2757291C (en) 2009-03-30 2017-05-23 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011030871A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 N-substituted heteroaryl compounds
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030872A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Sulfonamide compounds
JP2011057633A (en) * 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
WO2011030864A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Aniline compounds
WO2011030865A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Substituted zenzyl compounds
WO2011030873A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Benzyl compounds
EP2520570A4 (en) * 2009-12-25 2013-07-17 Ube Industries Aminopyridine compound
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc Substituted heterocyclic compounds for disease treatment
WO2014078434A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
SG11201507976YA (en) 2013-03-28 2015-10-29 Ube Industries Substituted biaryl compound
AP2016009502A0 (en) 2014-05-13 2016-10-31 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN106397149B (en) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 The preparation method of pentafluorobenzaldehyde
CN115636761A (en) * 2021-07-20 2023-01-24 中国石油天然气股份有限公司 Oil-soluble surfactant, oil displacement agent and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
DK0951282T3 (en) * 1996-12-20 2008-07-14 Pfizer Skeletal disease prevention and treatment with EP2 receptor subtype selective prostaglandin E2 agonists
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
WO2004078169A8 (en) 2005-04-21
WO2004078169A1 (en) 2004-09-16
AU2004216898A1 (en) 2004-09-16
KR20050105511A (en) 2005-11-04
CN1859903A (en) 2006-11-08
TW200424176A (en) 2004-11-16
BRPI0408061A (en) 2006-02-14
PL378748A1 (en) 2006-05-15
JP2006519250A (en) 2006-08-24
CA2518193A1 (en) 2004-09-16
EP1601351A1 (en) 2005-12-07
ZA200506532B (en) 2007-03-28
MXPA05009398A (en) 2005-12-05
NZ541828A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
CL2004000412A1 (en) USE OF AN EP2 RECEIVER SELECTIVE ANTAGONIST COMPOUND TO TREAT PULMONARY HYPERTENSION.
ECSP056037A (en) EP4 RECEIVER AGONIST, COMPOSITIONS AND PROCEDURES OF THE SAME
NO20041504L (en) Lactam derivatives as antagonists of human 11CBY receptors.
ECSP045203A (en) CYCLALCANINDOLS WITH REPLACEMENT WITH FLUORIDE AND ITS USE AS AN ANTAGONIST OF THE PROSTAGLANDINA D2 RECEIVER
NO20092101L (en) Ocular devices and methods for their manufacture and use.
SV2005002148A (en) "MODULATING COMPOUNDS OF THE C-KIT ACTIVITY AND USES OF THE SAME"
EA200501430A1 (en) Cannabinoid receptor ligands and their use
AR035275A1 (en) N-HETEROCICLYL-REPLACED TIENYLOXIPIRIMIDINS
EA200301215A1 (en) 5-HT RECEPTOR LIGANDS AND THEIR APPLICATION
GT200500309A (en) DERIVATIVES OF SULFONILBENCILIMIDAZOL
ECSP066756A (en) M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES OF THE SAME
CO6290757A2 (en) N- (2 (HETARL) ARI) ARILSULPHONAMIDS AND N- (2- (HETARIL) HETARIL) ARILSULFONAMIDS
CY1108430T1 (en) USE OF NETHERLANDS SIDE BASKET COMPETITORS WITH AMITERASE FOR ECOPARATOMETER CONTROLS IN HOUSEHOLD ANIMALS
CL2003002770A1 (en) COMPOUNDS DERIVED FROM PIRROL AND IMIDDAZOL; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM; PREPARATION PROCEDURE; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF DISEASES THAT ARE ASSOCIATED WITH THE MODULATION OF CANABINOID RECEPTORS
CO2021006482A2 (en) Cyclic ureas
WO2003047513A3 (en) Method for treating ocular hypertension
NO20052751D0 (en) Ophthalmic preparation for the treatment of ocular hypertension.
ATE415817T1 (en) AGROCHEMICAL FORMULATIONS
CL2003002769A1 (en) TIAZOLILPIRROL CARBOXAMIDE DERIVATIVE COMPOUNDS; PROCEDURE FOR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM; AND ITS USE FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES ASSOCIATED WITH THE CANABINOID RECEPTORS MODULATION
PE20070016A1 (en) N-LINKED HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE P2Y1 RECEIVER
DE60334905D1 (en) 1,5-DISUBSTITUTED PYRROLID-2-ON DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF EYE DISEASES SUCH AS e.g. GLAUCOMA
BRPI0519709A2 (en) tetraline and indane derivatives and their use as 5-ht antagonists
UY29802A1 (en) ANALOGS OF PHENYLETHYLAMINE AND ITS USE IN THE TREATMENT OF GLAUCOMA
UY28098A1 (en) USEFUL ANILINOPIRAZOL DERIVATIVES IN THE TREATMENT OF DIABETES
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES